Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.7.0.1
Commitments and Contingencies (Details) - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Commitments and Contingencies (Textual)    
Rent expense $ 171,294 $ 107,385
2011 Exclusive Agreement [Member]    
Commitments and Contingencies (Textual)    
Milestone payment $ 765,000  
License reduced percentage 50.00%  
Aggregate maintenance fees for first five years $ 80,000  
Maintenance fees annually after first five years $ 50,000  
Royalty percentage 2.00%  
Minimum royalty expense $ 75,000  
Royalty description The Company is required to pay royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of phase II clinical trials to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of phase I clinical trials).  
2013 Exclusive Agreement [Member]    
Commitments and Contingencies (Textual)    
Milestone payment $ 765,000  
License reduced percentage 50.00%  
Aggregate maintenance fees for first three years $ 7,500  
Maintenance fees annually after first five years $ 5,000  
Royalty percentage 2.00%  
Minimum royalty expense $ 75,000  
Royalty description The Company is required to pay The Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of phase II clinical trials to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of phase I clinical trials).  
License costs $ 10,000